Estrella Immunopharma (ESLA) Accounts Payables (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Accounts Payables of $14947.0 for Q1 2026, up 6.86% year-over-year from $13988.0 in Q1 2025, and down 97.01% quarter-over-quarter from $500000.0 in Q4 2025.
Estrella Immunopharma (ESLA) Accounts Payables (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Accounts Payables for 6 consecutive years, with $14947.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 6.86% year-over-year to $14947.0; the TTM figure through Mar 2026 stood at $14947.0 (up 6.86% YoY), while the FY2025 annual figure was $500000.0, up 11173.96% from the prior year.
- Accounts Payables declined to $14947.0 in Q1 2026 per ESLA's latest filing, from $500000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $9.3 million in Q3 2023 and bottomed at $4435.0 in Q4 2024.
- Historically, Accounts Payables has averaged $1.4 million across 5 years, with a median of $77076.0 in 2023.
- Annual changes were most pronounced in 2024 — Accounts Payables sank 99.95% — and 2025, when it jumped 11173.96%.
- Estrella Immunopharma's Accounts Payables stood at $329166.0 in 2022, then sank by 76.58% to $77076.0 in 2023, then sank by 94.25% to $4435.0 in 2024, then surged by 11173.96% to $500000.0 in 2025, then plunged by 97.01% to $14947.0 in 2026.
- Business Quant data shows ESLA's Accounts Payables at $14947.0 in Q1 2026, $500000.0 in Q4 2025, and $5631.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | 8,232.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8,232.00 |
| Mar 31, 2026 | 14,947.00 |
| Dec 31, 2025 | 500,000.00 |
| Sep 30, 2025 | 5,631.00 |
| Jun 30, 2025 | 8,154.00 |
| Mar 31, 2025 | 13,988.00 |
| Dec 31, 2024 | 4,435.00 |
| Sep 30, 2024 | 5,000.00 |
| Dec 31, 2023 | 77,076.00 |
| Sep 30, 2023 | 9.34 Mn |
| Jun 30, 2023 | 9.33 Mn |
| Mar 31, 2023 | 375,001.00 |
| Dec 31, 2022 | 329,166.00 |
| Sep 30, 2022 | 206,496.00 |
| Jun 30, 2022 | 106,447.00 |
| Mar 31, 2022 | 6,000.00 |
| Dec 31, 2021 | 3,000.00 |
| Sep 30, 2021 | 3,000.00 |